Alkermes

Alkermes plc is a biopharmaceutical company incorporated in Ireland and operating principally from the United States. It develops, manufactures, and commercializes medicines for serious diseases, with a concentration in neuroscience and mental-health conditions. Its portfolio has included long-acting injectable treatments for schizophrenia, bipolar I disorder, and alcohol or opioid dependence, as well as oral psychiatric medicines and products for addiction treatment. The company emerged from a business founded in 1987 around drug-delivery technology. Rather than building its identity as a conventional generic-drug manufacturer, Alkermes developed controlled-release and extended-release platforms intended to maintain therapeutic drug levels over longer periods. This technology orientation became central to its commercial strategy and helped the company participate in specialty pharmaceutical markets where formulation, adherence, and administration can be clinically important. Alkermes expanded through internal research, licensing arrangements, and acquisitions. Its collaboration with Johnson & Johnson brought the long-acting antipsychotic Risperdal Consta to market, while the acquisition of the pharmaceutical business of Elan Corporation in 2011 materially broadened Alkermes' development and commercial capabilities. That transaction added products and pipeline assets in central nervous system diseases and helped establish the scale associated with the modern Alkermes organization. The company is best known commercially for Vivitrol, a once-monthly injectable formulation of naltrexone used for alcohol dependence and for prevention of relapse to opioid dependence after detoxification; Aristada and Aristada Initio, long-acting aripiprazole products for schizophrenia; and Lybalvi, an oral combination of olanzapine and samidorphan for schizophrenia and bipolar I disorder. It has also commercialized or partnered on additional central-nervous-system products, including monotherapies and formulations designed to address adherence or tolerability challenges. Alkermes' positioning differs from that of a broad generic-drug company. Its business is centered on proprietary medicines, specialty commercialization, drug-delivery technologies, and a focused neuroscience pipeline. The company has also faced the commercial and regulatory risks associated with this model, including dependence on a limited number of important products, patent and exclusivity questions, manufacturing requirements for complex formulations, and public scrutiny of marketing practices in the addiction-treatment area. Alkermes remains an active Nasdaq-listed biopharmaceutical company. Its corporate structure is Irish, while much of its research, development, manufacturing, and commercial activity has been associated with the United States. The company continues to focus on medicines for schizophrenia, bipolar disorder, addiction, depression, and other central nervous system conditions.

Alkermes was established in 1987 as a drug-delivery company. Its early identity was built around technologies intended to release medicines gradually and improve the duration or consistency of treatment. This foundation later enabled the company to work with pharmaceutical partners and to develop its own specialty products. A major early commercial relationship was with Johnson & Johnson on Risperdal Consta, a long-acting injectable formulation of risperidone for schizophrenia. The product demonstrated the potential of extended-release delivery in psychiatry and gave Alkermes experience in formulation development, manufacturing, and commercialization of complex injectable medicines. Alkermes expanded its corporate and scientific footprint through the acquisition of the pharmaceutical business of Elan Corporation in 2011. The transaction added marketed products, research programs, employees, and infrastructure, and strengthened Alkermes' position as a company focused on central nervous system disorders. Following the acquisition, the company developed a broader portfolio spanning addiction, schizophrenia, bipolar disorder, and other psychiatric conditions. Vivitrol became one of Alkermes' most recognizable products. It is a once-monthly extended-release injectable suspension of naltrexone. The medicine is indicated for alcohol dependence and for prevention of relapse to opioid dependence following opioid detoxification. Its monthly administration was positioned as an alternative to daily oral treatment, particularly where adherence is a significant challenge. Vivitrol also became the subject of debate over pricing, evidence, access, and promotional practices in the treatment of opioid-use disorder. Alkermes subsequently commercialized Aristada, a long-acting injectable formulation of aripiprazole lauroxil for schizophrenia, and Aristada Initio, a one-day initiation option intended to help begin Aristada treatment. These products extended the company's role in long-acting psychiatric therapy and reflected its continuing emphasis on formulations that may reduce dosing frequency. The company entered the oral psychiatric market with Lybalvi, a combination of olanzapine and samidorphan. The FDA approved Lybalvi in 2021 for schizophrenia and bipolar I disorder in adults. The product was designed to combine olanzapine's established antipsychotic activity with samidorphan, an opioid-receptor modulator, in an effort to address weight-gain concerns associated with olanzapine treatment. Alkermes also developed an oncology business, but later chose to separate that operation from its core neuroscience activities. The oncology assets were transferred into a new independent company, SpringWorks Therapeutics, which became publicly traded. The separation sharpened Alkermes' strategic focus on neuroscience and specialty medicines. In the late 2010s, Alkermes faced legal and public scrutiny over promotion of Vivitrol. In 2019, the U.S. Department of Justice announced a settlement concerning allegations that the company promoted Vivitrol for uses or in ways not supported by its approved labeling and made related representations. Alkermes paid $125 million to resolve the matter without admitting liability. The episode remains part of the company's regulatory and reputational history. Today, Alkermes is an Irish-incorporated, Nasdaq-listed biopharmaceutical company with substantial U.S. operations. Its business combines proprietary medicines, long-acting injectable technology, specialty sales capabilities, and a neuroscience research pipeline. The company continues to compete in markets shaped by clinical evidence, reimbursement, regulatory review, manufacturing complexity, patent protection, and the need for better adherence in chronic psychiatric and addiction treatment.

1. 2021Lybalvi approved

   The FDA approved Lybalvi for adults with schizophrenia and adults with bipolar I disorder.

   Source
2. 2020Oncology business separated

   Alkermes separated its oncology business into SpringWorks Therapeutics and refocused on neuroscience.

   Source
3. 2019Vivitrol settlement announced

   Alkermes agreed to pay $125 million to resolve U.S. Department of Justice allegations concerning Vivitrol marketing practices.

   Source
4. 2018Aristada Initio approved

   The FDA approved Aristada Initio as a one-day initiation option for Aristada treatment in adults with schizophrenia.

   Source
5. 2013Aristada approved

   The FDA approved Aristada, a long-acting injectable formulation of aripiprazole lauroxil for schizophrenia.

   Source
6. 2011Elan pharmaceutical business acquired

   Alkermes acquired Elan Corporation's pharmaceutical business, significantly expanding its products, pipeline, and central nervous system capabilities.

   Source
7. 1987Company founded

   Alkermes was established as a drug-delivery company.

   Source

Specialty biopharmaceutical company focused on neuroscience, addiction medicine, and proprietary extended-release drug-delivery technologies.

• VivitrolAddiction medicine2006

  Vivitrol is an extended-release injectable suspension of naltrexone administered once monthly. It is approved for the treatment of alcohol dependence and for prevention of relapse to opioid dependence after opioid detoxification. The product is one of Alkermes' most important commercial assets and exemplifies its focus on long-acting delivery and adherence in chronic or relapsing conditions.

• AristadaLong-acting antipsychotic2015

  Aristada is a long-acting injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults. Its dosing intervals are longer than those of daily oral therapy, making it part of Alkermes' strategy to provide maintenance treatment options that may support adherence and reduce the burden of daily medication-taking.

• Aristada InitioLong-acting antipsychotic initiation product2018

  Aristada Initio is a single-dose injectable formulation used to initiate Aristada treatment in adults with schizophrenia. It was developed to simplify the transition to the long-acting Aristada regimen and is used with oral aripiprazole under the approved treatment protocol.

• LybalviAtypical antipsychotic2021

  Lybalvi is an oral fixed-dose combination of olanzapine and samidorphan. It is approved for the treatment of schizophrenia in adults and for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. Its development reflects Alkermes' attempt to combine established antipsychotic efficacy with a component intended to address olanzapine-associated weight-gain concerns.

• Risperdal ConstaLong-acting antipsychotic formulation2003

  Risperdal Consta is a long-acting injectable formulation of risperidone developed through a collaboration between Alkermes and Johnson & Johnson. It became an early commercial example of Alkermes' extended-release microsphere technology in psychiatry and helped establish the company's capabilities in complex injectable drug delivery.

• Vivitrol addiction-treatment promotion

  United States

  Alkermes promoted Vivitrol to healthcare providers, public agencies, and organizations involved in addiction treatment, emphasizing monthly administration and the role of medication in recovery programs.

  Outcome. The product became a prominent branded treatment in the U.S. addiction-medicine market, while its promotion and pricing generated substantial public and regulatory scrutiny.

  Source

• 2021Launch of LybalviProduct launch

  The company pursued an oral psychiatric product addressing schizophrenia and bipolar I disorder.

  What changed. Following FDA approval, Alkermes introduced Lybalvi in the United States.

  Aftermath. Lybalvi became a newer branded component of Alkermes' psychiatry portfolio.

  Source
• 2020Separation of oncology operationsStrategy

  Alkermes determined that a separate company would allow its oncology assets to pursue their own development and financing strategy.

  What changed. The oncology business was separated into SpringWorks Therapeutics.

  Aftermath. Alkermes became more concentrated on neuroscience and specialty medicines.

  Source
• 2011Acquisition of Elan's pharmaceutical businessM&A

  Alkermes sought to expand its commercial portfolio and central nervous system pipeline.

  What changed. The company acquired Elan Corporation's pharmaceutical business and related assets.

  Aftermath. The transaction broadened Alkermes' products, development programs, and operational scale.

  Source

• 2019Vivitrol marketing settlementControversy

  The U.S. Department of Justice announced that Alkermes agreed to pay $125 million to resolve allegations involving the marketing of Vivitrol. The allegations included promotion for uses or in ways not supported by the product's approved labeling. The settlement did not include an admission of liability by the company.

  Source

• 2021Alkermes receives FDA approval for Lybalvi

  The U.S. Food and Drug Administration approved Lybalvi, an oral combination of olanzapine and samidorphan, for adults with schizophrenia and adults with bipolar I disorder.

  Product launchRegulation
  Source
• 2020Alkermes announces separation of its oncology business

  Alkermes announced plans to separate its oncology business into a new company, later named SpringWorks Therapeutics, allowing Alkermes to concentrate more closely on neuroscience.

  M&A
  Source

1. Alkermes company overview
2. Alkermes leadership
3. U.S. Department of Justice Vivitrol settlement
4. FDA approval of Lybalvi
5. Alkermes company news and transactions
6. Aristada approved
7. Aristada Initio approved